Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Pharmacology 2023;108(6):589–598 doi 10.1159/000527186
The results of a Bayesian network meta-analysis by Lee and Song showed that JAK inhibitors were more likely to achieve remission and LDA in DMARD-naive RA patients than MTX. However, there were no significant differences in remission rates nor LDA rates between the JAK inhibitors investigated.
This meta-analysis included four RCTs that captures remission (DAS28-CRP<2.6) and LDA (DAS28-CRP≤3.2) rates resulting from treatment with tofacitinib, baricitinib, upadacitinib, and filgotinib monotherapy, versus MTX in patients with DMARD-naive RA.
